SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).

S1400D is a biomarker-driven therapeutic substudy Lung-MAP evaluate fibroblast growth factor (FGF) receptor (FGFR) inhibitor AZD4547 in patients with squamous cell FGF-activated pathway.

This is the first Phase II trials to evaluate AZD4547 as a targeted approach in previously treated patients with squamous cell NSCLC FGFR-altered and is the first demonstration of the successful execution and behavior of a national umbrella protocol in this disease setting.Eligible patients had tumoral FGFR change or mutations and have progressive disease after at least one line of platinum-based systemic therapy.

Patients received AZD4547 80 mg twice a day orally. The primary endpoint was the response by Response Evaluation Criteria in Solid Tumors version 1.1; Secondary endpoints included progression-free survival, overall survival, and duration of response (DOR) .Ninety-two patients assigned to S1400D, 43 were enrolled, and 27 patients were treated AZD4547 was evaluated. evaluable patients was predominantly white (n = 24, 89%), median age 66 years (range, 49-88 years old) and women (n = 7, 26%). FGFR changes include FGFR1 amplification (n = 23; 85%), FGFR3 amplification (n = 2; 7%), FGFR3 S249C (n = 2; 7%), and FGFR3 fusion (n = 1; 4%).

Treatment with ADZ4547 tolerated; Grade 3 adverse events occurred in six patients, and one patient had grade 4 sepsis. Of the 27 patient-evaluated response, one patient with FGFR3 S249C had an unconfirmed partial response with dor 1.5 months and 1 patient with FGFR1 amplification has confirmed partial response with a bang of 2.9 months (7%, 95% confidence interval [CI ]: 0% -17%). Median progression-free survival and overall survival for AZD4547-treated cohort of 2.7 months (95% CI: 1.4 to 4.5 months) and 7.5 months (95% CI: 3.7 to 9.3 months). AZD4547 has an acceptable safety profile but minimal activity in this group is dominated FGFR1 / FGFR3-reinforced. Evaluation of other targeted agents in Lung-MAP is underway.

SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).
SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously Treated Patients With Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Substudy).

the important role of fibroblast growth factor signaling pathways in Ewing sarcoma octamer binding transcription factor 4 -mediated cell proliferation and tumorigenesis.

certain bone and soft tissue (BST) tumors harbor chromosomal translocation [t (6; 22) (p21; q12)], which fuses Ewing’s sarcoma (EWS) gene at 22q12 with octamer binding transcription factor 4 (Oct-4) gene on the 6p21 , resulting chimeric EWS-Oct-4 protein that has the ability of high transactivation.

Although the abnormal activation of signaling pathways can lead to the development of human cancer, pathways that underlie this process in tumor BST humans remain poorly explored. Here, we investigate the functional significance of fibroblast growth factor (FGF) signaling in human tumor BST. To identify the gene (s) involved in the FGF signaling pathway and potentially regulated by EWS-Oct-4 (also called EWS-POU5F1) we did an analysis of RNA-Seq, electrophoretic mobility shift test, chromatin immunoprecipitation test, and test xenograft.

Treating the cells expressing GBS6 or ZHBTc4-EWS-Oct-4 with a small molecule FGF receptor (FGFR) inhibitor PD173074, NVPBGJ398, ponatinib, and dovitinib suppressed cell proliferation. Gene expression analysis revealed that, among the 22 FGF and four family members Fgfr, FGF-4 showed the highest upregulation (by 145-fold) in cells expressing EWS ZHBTc4-October-4. computer-aided analysis to identify sites EWS-October-4-binding allegedly at + 3017 / + 3024, shows that the EWS-October-4 Organize FGF-4 expression in human tumor BST.

P38 mAb

MBS435304-01mL 0.1mL
EUR 660

P38 mAb

MBS435304-5x01mL 5x0.1mL
EUR 2655

p38 MAPK

E8ET1702-65 100ul
EUR 275
Description: Available in various conjugation types.

Mxi2, p38

MBS603655-01mg 0.1mg
EUR 820

Mxi2, p38

MBS603655-5x01mg 5x0.1mg
EUR 3530

p38 MAPK

MBS8534372-01mL 0.1mL
EUR 345

p38 MAPK

MBS8534372-01mLAF405L 0.1mL(AF405L)
EUR 565

p38 MAPK

MBS8534372-01mLAF405S 0.1mL(AF405S)
EUR 565

p38 MAPK

MBS8534372-01mLAF610 0.1mL(AF610)
EUR 565

p38 MAPK

MBS8534372-01mLAF635 0.1mL(AF635)
EUR 565

p38 protein

E20-80078 20ug
EUR 275
Description: N/A

p38 protein

E20-80079 20ug
EUR 275
Description: N/A

p38 protein

MBS8526800-002mg 0.02mg
EUR 345

p38 protein

MBS8526800-5x002mg 5x0.02mg
EUR 1410

p38 protein

MBS8526801-002mg 0.02mg
EUR 345

p38 protein

MBS8526801-5x002mg 5x0.02mg
EUR 1410

p38 Antibody

20-abx141038
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ul
  • 200 ul
  • 30 ul

p38 Antibody

20-abx133223
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ul
  • 200 ul
  • 30 ul

p38 Antibody

20-abx007541
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ul
  • 200 ul
  • 30 ul

p38 Antibody

48644 100ul
EUR 499

p38 Antibody

48644-100ul 100ul
EUR 399.6

p38 Antibody

48644-50ul 50ul
EUR 286.8

p38 Antibody

35478 100ul
EUR 479

p38 Antibody

35478-100ul 100ul
EUR 468

p38 Antibody

abx236076-100ug 100 ug
EUR 577.2

p38 Antibody

E38PA4721 100ul
EUR 225
Description: Available in various conjugation types.

p38 Antibody

E38PA5060 100ul
EUR 225
Description: Available in various conjugation types.

p38 Antibody

E38PA5094 100ul
EUR 225
Description: Available in various conjugation types.

p38 Antibody

E38PA7126 100ul
EUR 225
Description: Available in various conjugation types.

p38 Antibody

E38PA3186 100ul
EUR 225
Description: Available in various conjugation types.

p38 antibody

70R-51505 100 ul
EUR 242
Description: Purified Polyclonal p38 antibody

p38 antibody

70R-51506 100 ul
EUR 286
Description: Purified Polyclonal p38 antibody

p38 Antibody

abx236076-100g 100 µg
EUR 350

p38 Antibody

MBS9409774-01mL 0.1mL
EUR 420

p38 Antibody

MBS9409774-5x01mL 5x0.1mL
EUR 1740

p38 Antibody

MBS806203-0025mL 0.025mL
EUR 320

p38 Antibody

MBS8002013-0025mL 0.025mL
EUR 315

p38 Antibody

MBS8002013-5x0025mL 5x0.025mL
EUR 890

p38 Antibody

MBS805089-01mL 0.1mL
EUR 425

p38 Antibody

MBS805089-5x01mL 5x0.1mL
EUR 1350

p38 Antibody

MBS8584173-01mL 0.1mL
EUR 305

p38 Antibody

MBS8584173-01mLAF405L 0.1mL(AF405L)
EUR 465

p38 Antibody

MBS8584173-01mLAF405S 0.1mL(AF405S)
EUR 465

p38 Antibody

MBS8584173-01mLAF610 0.1mL(AF610)
EUR 465

p38 Antibody

MBS8584173-01mLAF635 0.1mL(AF635)
EUR 465

p38 Antibody

MBS8582665-01mL 0.1mL
EUR 305

p38 Antibody

MBS8582665-01mLAF405L 0.1mL(AF405L)
EUR 465

p38 Antibody

MBS8582665-01mLAF405S 0.1mL(AF405S)
EUR 465

p38 Antibody

MBS8582665-01mLAF610 0.1mL(AF610)
EUR 465

p38 Antibody

MBS8582665-01mLAF635 0.1mL(AF635)
EUR 465

p38 Antibody

MBS8582905-01mL 0.1mL
EUR 305

p38 Antibody

MBS8582905-01mLAF405L 0.1mL(AF405L)
EUR 465

p38 Antibody

MBS8582905-01mLAF405S 0.1mL(AF405S)
EUR 465

p38 Antibody

MBS8582905-01mLAF610 0.1mL(AF610)
EUR 465

p38 Antibody

MBS8582905-01mLAF635 0.1mL(AF635)
EUR 465

p38 Antibody

MBS8582923-01mL 0.1mL
EUR 305

p38 Antibody

MBS8582923-01mLAF405L 0.1mL(AF405L)
EUR 465

p38 Antibody

MBS8582923-01mLAF405S 0.1mL(AF405S)
EUR 465

p38 Antibody

MBS8582923-01mLAF610 0.1mL(AF610)
EUR 465

p38 Antibody

MBS8582923-01mLAF635 0.1mL(AF635)
EUR 465

p38 Antibody

MBS8581787-01mL 0.1mL
EUR 305

p38 Antibody

MBS8581787-01mLAF405L 0.1mL(AF405L)
EUR 465

p38 Antibody

MBS8581787-01mLAF405S 0.1mL(AF405S)
EUR 465

p38 Antibody

MBS8581787-01mLAF610 0.1mL(AF610)
EUR 465

p38 Antibody

MBS8581787-01mLAF635 0.1mL(AF635)
EUR 465

p38 Antibody

MBS5316121-01mL 0.1mL
EUR 460

p38 Antibody

MBS5316121-5x01mL 5x0.1mL
EUR 1920

p38 Antibody

MBS5316122-01mL 0.1mL
EUR 535

p38 Antibody

MBS5316122-5x01mL 5x0.1mL
EUR 2270

p38 Antibody

MBS9435492-005mL 0.05mL
EUR 325

p38 Antibody

MBS9435492-01mL 0.1mL
EUR 435

p38 Antibody

MBS9435492-5x01mL 5x0.1mL
EUR 1810

p38 Antibody

MBS9508977-005mL 0.05mL
EUR 285

p38 Antibody

MBS9508977-01mL 0.1mL
EUR 385

p38 Antibody

MBS9508977-5x01mL 5x0.1mL
EUR 1590

p38 Antibody

B0798-100ul 100μl
EUR 217
Description: p38 Rabbit Polyclonal Antibody

p38 Antibody

B0798-50ul 50μl
EUR 143.5
Description: p38 Rabbit Polyclonal Antibody

p38 Antibody

B0799-100ul 100μl
EUR 217
Description: p38 Rabbit Polyclonal Antibody

p38 Antibody

B0799-50ul 50μl
EUR 143.5
Description: p38 Rabbit Polyclonal Antibody

p38 Antibody

B7178-100ul 100μl
EUR 217
Description: p38 Rabbit Polyclonal Antibody

p38 Antibody

B7178-50ul 50μl
EUR 143.5
Description: p38 Rabbit Polyclonal Antibody

p38 Substrate

MBS517838-1mg 1mg
EUR 205

p38 Substrate

MBS517838-5x1mg 5x1mg
EUR 675

MAP Kinase p38, Control Cell Extracts (Mitogen Activated Protein Kinase p38, MAPK p38)

MBS657552-10Blots 10Blots
EUR 430

MAP Kinase p38, Control Cell Extracts (Mitogen Activated Protein Kinase p38, MAPK p38)

MBS657552-5x10Blots 5x10Blots
EUR 1785

MAP Kinase p38, phosphorylated (Thr180, Tyr182) (Mitogen Activated Protein Kinase p38, MAPK p38)

MBS630803-02mL 0.2mL
EUR 650

MAP Kinase p38, phosphorylated (Thr180, Tyr182) (Mitogen Activated Protein Kinase p38, MAPK p38)

MBS630803-06mL 0.6mL
EUR 1175

MAP Kinase p38, phosphorylated (Thr180, Tyr182) (Mitogen Activated Protein Kinase p38, MAPK p38)

MBS630803-5x06mL 5x0.6mL
EUR 5140

MAP Kinase p38, phosphorylated (Thr180, Ty182) (Mitogen Activated Protein Kinase p38, MAPK p38)

MBS632290-02mL 0.2mL
EUR 660

MAP Kinase p38, phosphorylated (Thr180, Ty182) (Mitogen Activated Protein Kinase p38, MAPK p38)

MBS632290-5x02mL 5x0.2mL
EUR 2810

MAP Kinase p38, phosphorylated (Thr180, Ty182) (Mitogen Activated Protein Kinase p38, MAPK p38)

MBS633592-01mL 0.1mL
EUR 695

MAP Kinase p38, phosphorylated (Thr180, Ty182) (Mitogen Activated Protein Kinase p38, MAPK p38)

MBS633592-5x01mL 5x0.1mL
EUR 2985

MAP Kinase p38, phosphorylated (Thr180, Tyr182) (Mitogen Activated Protein Kinase p38, MAPK p38)

MBS627818-10Blots 10Blots
EUR 875

MAP Kinase p38, phosphorylated (Thr180, Tyr182) (Mitogen Activated Protein Kinase p38, MAPK p38)

MBS627818-5x10Blots 5x10Blots
EUR 3785

SB-203580 p38 MAPK(p38 MAP kinase) Inhibitor

E1B1863 1mg
EUR 85

SB-203580 p38 MAPK (p38 MAP kinase) Inhibitor

MBS8579825-1mg 1mg
EUR 180

SB-203580 p38 MAPK (p38 MAP kinase) Inhibitor

MBS8579825-5x1mg 5x1mg
EUR 660

p38 (411-425) M.leprae

MBS8246858-10mg 10mg
EUR 675

p38 (411-425) M.leprae

MBS8246858-1mg 1mg
EUR 255

p38 (411-425) M.leprae

MBS8246858-5mg 5mg
EUR 480

p38 (411-425) M.leprae

MBS8246858-5x10mg 5x10mg
EUR 2955

MAP Kinase p38, phosphorylated (Thr180, Ty182) (Mitogen Activated Protein Kinase p38, MAPK p38) (Agarose)

MBS631660-04mL 0.4mL
EUR 670

MAP Kinase p38, phosphorylated (Thr180, Ty182) (Mitogen Activated Protein Kinase p38, MAPK p38) (Agarose)

MBS631660-5x04mL 5x0.4mL
EUR 2870

Anti - p38-a

MBS684252-002mL 0.02mL
EUR 270

Anti - p38-a

MBS684252-005mL 0.05mL
EUR 485

Anti - p38-a

MBS684252-01mL 0.1mL
EUR 720

Anti - p38-a

MBS684252-5x01mL 5x0.1mL
EUR 2925

Anti - p38-b

MBS684253-002mL 0.02mL
EUR 270

Anti - p38-b

MBS684253-005mL 0.05mL
EUR 485

Anti - p38-b

MBS684253-01mL 0.1mL
EUR 720

Anti - p38-b

MBS684253-5x01mL 5x0.1mL
EUR 2925

Anti - p38-g

MBS684254-002mL 0.02mL
EUR 270

Anti - p38-g

MBS684254-005mL 0.05mL
EUR 485

Anti - p38-g

MBS684254-01mL 0.1mL
EUR 720

Anti - p38-g

MBS684254-5x01mL 5x0.1mL
EUR 2925

Anti - p38-d

MBS684255-002mL 0.02mL
EUR 270

Anti - p38-d

MBS684255-005mL 0.05mL
EUR 485

Anti - p38-d

MBS684255-01mL 0.1mL
EUR 720

Anti - p38-d

MBS684255-5x01mL 5x0.1mL
EUR 2925

p38 Mouse mAb

E2220879 100ul
EUR 225
Description: Available in various conjugation types.

p38 Mouse mAb

E2222580 100ul
EUR 255
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody

p38 Mouse mAb

MBS8539086-01mL 0.1mL
EUR 305

p38 Mouse mAb

MBS8539086-01mLAF405L 0.1mL(AF405L)
EUR 565

p38 Mouse mAb

MBS8539086-01mLAF405S 0.1mL(AF405S)
EUR 565

p38 Mouse mAb

MBS8539086-01mLAF610 0.1mL(AF610)
EUR 565

p38 Mouse mAb

MBS8539086-01mLAF635 0.1mL(AF635)
EUR 565

p38 Rabbit pAb

E2340697 100ul
EUR 225
Description: Available in various conjugation types.

p38 Rabbit pAb

E2380881 100ul
EUR 225
Description: Available in various conjugation types.

p38 Rabbit pAb

E2381051 100ul
EUR 225
Description: Available in various conjugation types.

p38 Rabbit mAb

E2R25239 100μl
EUR 225
Description: Available in various conjugation types.

p38 Rabbit mAb

E2R27123 100μl
EUR 225
Description: Available in various conjugation types.

p38 Rabbit pAb

E2251338 100ul
EUR 225
Description: Available in various conjugation types.

p38 Rabbit pAb

E2251719 100ul
EUR 225
Description: Available in various conjugation types.

anti-Crk p38

YF-PA11088 50 ul
EUR 435.6
Description: Mouse polyclonal to Crk p38

anti-Crk p38

YF-PA11089 50 ug
EUR 435.6
Description: Mouse polyclonal to Crk p38

anti-Crk p38

YF-PA11090 100 ug
EUR 483.6
Description: Rabbit polyclonal to Crk p38

anti-Crk p38

YF-PA23509 50 ul
EUR 400.8
Description: Mouse polyclonal to Crk p38

p38 Rabbit pAb

MBS8539985-01mL 0.1mL
EUR 305

p38 Rabbit pAb

MBS8539985-01mLAF405L 0.1mL(AF405L)
EUR 565

p38 Rabbit pAb

MBS8539985-01mLAF405S 0.1mL(AF405S)
EUR 565

p38 Rabbit pAb

MBS8539985-01mLAF610 0.1mL(AF610)
EUR 565

FGF-4 enhancer construction showed that EWS-October-4 transactivated reporter FGF-4 gene in vitro, and that overexpression of EWS-Oct-4 stimulates endogenous FGF-4 gene expression in vivo. \

April

Related Posts

Zeptometrix Coronavirus

Zeptometrix Coronavirus

Fibroblast growth factor 23 and cognitive impairment: The health, aging, and body composition study

Fibroblast growth factor 23 and cognitive impairment: The health, aging, and body composition study

Investigating the causal effect of fibroblast growth factor 23 on osteoporosis and cardiometabolic disorders: A Mendelian randomization study

Investigating the causal effect of fibroblast growth factor 23 on osteoporosis and cardiometabolic disorders: A Mendelian randomization study

Effect of HBO therapy on adipose-derived stem cells, fibroblasts and co-cultures: In vitro study of oxidative stress, angiogenic potential and production of pro-inflammatory growth factors in co-cultures1

Effect of HBO therapy on adipose-derived stem cells, fibroblasts and co-cultures: In vitro study of oxidative stress, angiogenic potential and production of pro-inflammatory growth factors in co-cultures1

No Comment

Leave a Reply

Your email address will not be published.

Recent Posts

Tags

July 2024
M T W T F S S
1234567
891011121314
15161718192021
22232425262728
293031  

Categories